Phase 1 Study Of Jnj-67856633, A First-In-Human Highly Selective Malt1 Inhibitor, In Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-Nhl) And Chronic Lymphocytic Leukemia (Cll)
JNJ-67856633
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: Phase 1 Study Of Jnj-67856633, A First-In-Human Highly Selective Malt1 Inhibitor, In Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-Nhl) And Chronic Lymphocytic Leukemia (Cll) ### Output: JNJ-67856633